The White House has begun reviewing a next FDA prescription drug user-fee deal covering 2028 through 2032, according to sources familiar with the discussions. The proposal sets the funding mechanism that will determine how much the agency can invest in staffing, review capacity, and process initiatives as new drug pipelines continue to expand. The user-fee process is closely watched by the biopharma industry because it influences development timelines and the pace of regulatory decisions for both novel therapeutics and supplemental indications. Any changes demanded during White House review could affect how quickly negotiated targets are implemented. Companies and trade groups typically treat these intervals as a major inflection point for near-term FDA operating expectations, especially around early development support, BLA review capacity, and inspection throughput.